Northwest Biotherapeutics Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Northwest Biotherapeutics Inc.

NWBO 0.240

+3.4%

Oct 30 3:58 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy

2/6/2017 10:47:11 AM

of 759

Rkmatters	Monday, 02/06/17 10:21:07 AM
Re: CaptainOblivious post# 100374
Post # of 100413

They were not transparent. We do not know when PFS was hit, only that it had not been reached when they reached out for in October.

I also found that clinical halt lift fascinating. To me it means that they did not enroll a single patient after the halt was initiated, in August 2015. I would imagine that the expanded access arm stayed open to catch those excess patients who may have been in the last screen step. And I also think that it is important to note that this PFS endpoint is considered a final IA. This would be the point that they submit for AA. The moment they let the regulatory bodies know the PFS endpoint was hit, the halt was lifted. I believe that means results are good and that a possible AA process will begin by the DMC. That was my take away upon reading the non-transparent PR.

siliconinvestor.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next